EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Why does GLP ‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP ‐1 agonist alone in obese adults without type 2 diabetes?

Yuchen Jiang, Huijuan Zhu, Fengying Gong iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16106 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Yuchen Jiang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of…. Hauptthemen laut MEDLINE: Obesity, Weight Loss, Glucagon-Like Peptide 1, Gastric Inhibitory Polypeptide. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 146 Literaturangaben. Gefördert von: the CAMS Innovation Fund for Medical Sciences (CIFMS), the National Natural Science Foundation of China, the Beijing Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is a chronic condition demanding effective treatment strategies, among which pharmacotherapy plays a critical role. As glucagon‐like peptide‐1 (GLP‐1) agonist approved by the Food and Drug Administration (FDA) for long‐term weight management in adults with obesity, liraglutide and semaglutide have great weight loss effect through reducing food intake and delaying gastric emptying. The emergence of unimolecular polypharmacology, which utilizes single molecules to simultaneously target multiple receptors or pathways, marked a revolutionary improvement in GLP‐1‐based obesity pharmacotherapy. The dual agonist tirzepatide activates both GLP‐1 and glucose‐dependent insulinotropic polypeptide (GIP) receptors and has shown enhanced potency for weight loss compared to conventional GLP‐1 mono agonist. Furthermore, emerging data suggests that unimolecular GLP‐1/glucagon (GCG) dual agonist, as well as GLP‐1/GIP/GCG triple agonist, may offer superior weight loss efficacy over GLP‐1 agonist. This review summarizes the comprehensive mechanisms underlying the pronounced advantages of GLP‐1/GIP dual agonist, GLP‐1/GCG dual agonist and GLP‐1/GIP/GCG triple agonist over GLP‐1 mono agonist in weight reduction in obese adults without type 2 diabetes. A deeper understanding of these unimolecular multitargeting GLP‐1‐based agonists will provide insights for their clinical application and guide the development of new drugs for obesity treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityWeight LossGlucagon-Like Peptide 1Gastric Inhibitory PolypeptideAnti-Obesity AgentsHumansLiraglutideDiabetes Mellitus, Type 2Glucagon-Like PeptidesDrug Therapy, CombinationTirzepatideReceptors, Gastrointestinal HormoneAdultGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSemaglutide

Stichwörter der Autor:innen

GIPGLP‐1antiobesity drugdrug mechanismglucagonweight management

Substanzen

Glucagon-Like Peptide 1Gastric Inhibitory PolypeptideLiraglutideGlucagon-Like PeptidesTirzepatideReceptors, Gastrointestinal HormoneAnti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSemaglutide

Autor:innen und Institutionen

  • Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.

ORCID-Profile: Fengying Gong

Förderung

  • the CAMS Innovation Fund for Medical Sciences (CIFMS)
  • the National Natural Science Foundation of China
  • the Beijing Natural Science Foundation
  • the National Key Clinical Specialty Capacity Improvement Project
  • the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
  • the PUMCH Foundation

Zitieren

APA

Jiang, Y., Zhu, H., & Gong, F. (2025). Why does GLP ‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP ‐1 agonist alone in obese adults without type 2 diabetes?. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16106

Vancouver

Jiang Y, Zhu H, Gong F. Why does GLP ‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP ‐1 agonist alone in obese adults without type 2 diabetes?. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16106

BibTeX
@article{Jiang2025,
  author = {Jiang, Yuchen and Zhu, Huijuan and Gong, Fengying},
  title = {Why does GLP ‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP ‐1 agonist alone in obese adults without type 2 diabetes?},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16106}
}
Kostenlos starten →